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Preclinical studies have suggested that sunitinib
accelerates metastases in animals, ascribing this to
inhibition of the vascular endothelial growth factor
receptor or the tumor’s adaptation. To address
whether sunitinib accelerates tumors in humans,
we analyzed data from the pivotal randomized phase
III trial comparing sunitinib and interferon alfa in
patients with metastatic renal cell carcinoma. The
evidence clearly shows that sunitinib was not harm-
ful, did not accelerate tumor growth, and did not
shorten survival. Specifically, neither longer sunitinib
treatment nor a greater effect of sunitinib on tumors
reduced survival. Sunitinib did reduce the tumor’s
growth rate while administered, thereby improving
survival, without appearing to alter tumor biology
after discontinuation. Concerns arising from animal
models do not apply to patients receiving sunitinib
and likely will not apply to similar agents.INTRODUCTION
Folkman first proposed angiogenesis, considered one of the
hallmarks of cancer, as a therapeutic target more than four
decades ago (Folkman, 1971; Folkman et al., 1971; Hanahan
and Weinberg, 2011). In recent years the Food and Drug Admin-
istration has approved a number of drugs that in preclinical
models target the molecular mechanisms thought to promote
angiogenesis. In addition to targeting proteins involved in angio-
genesis, most of these drugs have a broader spectrum and also
influence other molecular processes. One of the targets of these
‘‘antiangiogenic’’ drugs is the family of vascular endothelial
growth factors (VEGFs) and their receptors (VEGFRs), which
promote new blood vessel growth during embryogenesis,
wound healing, and tumorigenesis (Ferrara, 2009; Potente
et al., 2011). VEGFs promote the dimerization of their targets
(VEGFRs), membrane receptor tyrosine kinases (TRKs), leading
to their phosphorylation. Subsequently, these phosphorylated
receptors recruit intracellular proteins that upregulate pathways
promoting blood vessel formation. In mammals, there are threeCreceptors— VEGFR1, VEGFR2, and VEGFR3—and five ligand
proteins—VEGFA, VEGFB, VEGFC, VEGF–D, and placenta
growth factor. During the early stages of tumor growth, hypoxia
upregulates VEGFA and VEGFR1 expression, making these
proteins attractive as drug targets (Kowanetz and Ferrara, 2006).
Sunitinib is a tyrosine kinase inhibitor that has multiple targets
(Papaetis and Syrigos, 2009; Heng and Kollmannsberger, 2010).
It was approved for treatment of metastatic renal cell carcinoma
(mRCC) on the basis of its ability to significantly delay the time to
tumor progression in a randomized clinical trial and was subse-
quently shown to prolong survival (Motzer et al., 2007, 2009). A
characteristic of renal cell carcinoma is its high vascularity, a
property ascribed to alterations in the Von Hippel-Lindau tumor
suppressor and HIFa that, in turn, mediate the overexpression
of VEGF. Recently, however, studies in animal models have
raised the possibility that antiangiogenic drugs might create a
favorable environment for ‘‘acceleration’’ of metastasis (Ebos
et al., 2009; Pa`ez-Ribes et al., 2009). While an analysis of tumor
growth kinetics in patients receiving the anti-VEGF antibody bev-
acizumab suggested that it could accelerate disease progres-
sion after the end of treatment (Stein et al., 2008), such evidence
does not exist for small molecule inhibitors of the VEGFR (Stein
et al., 2012). The study reported here assessed the possibility of
acceleration of tumor growth in patients treated with the VEGFR
inhibitor sunitinib. We analyzed data from the pivotal clinical trial
comparing sunitinib and interferon alfa that led to sunitinib’s
approval in metastatic renal cell carcinoma by the Food and
Drug Administration in the United States and the European
Medicines Agency in Europe (Motzer et al., 2007, 2009; Stein
et al., 2012).RESULTS
Sunitinib treatment reduced the quantity of tumors in a majority
of patients, and in approximately 30% of patients it reduced
the tumor quantity to a level sufficient to qualify as a "response,"
as defined by response evaluation criteria in solid tumors
(RECIST) (Therasse et al., 2000). Figure 1A is a schematic repre-
sentation of the time course of the measured tumor in a case
where the tumor initially shrinks in size when treated with suniti-
nib. The figure presents the definitions used in this manuscript.
Tumor shrinkage is observed initially because the fraction of
tumor that is sensitive to the drug is greater, indeed oftenell Reports 3, 277–281, February 21, 2013 ª2013 The Authors 277
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Figure 1. Definitions and Overall Results
(A) Example of time course of tumor regression and growth in a ‘‘typical’’
patient receiving sunitinib and visual representation of terms used. The red
symbols depict the actual tumor quantities measured while the patient was
enrolled in the clinical trial. The blue symbols depict an estimation of tumor
quantity after treatment was discontinued. Abbreviations are as follows: TOT,
time on treatment; PPS, postprotocol survival; OS, overall survival.
(B) PPS for patients randomized to receive sunitinib and those randomized to
receive interferon alfa. The differences are statistically significant at p = 0.006.
Figure 2. Effect of Sunitinib on Survival Outcomes
(A and B) Correlations between TOT with sunitinib and either PPS (A) (Rsq =
0.003; p = 0.43) or OS (B) (Rsq = 0.49; p < 0.001), demonstrating the lack of
an effect of duration of sunitinib exposure (TOT) on survival following the
discontinuation of sunitinib (PPS).
much greater, than the fraction that is resistant and the net quan-
tity of tumor initially decreases over time. However, in >99% of
patients, tumors eventually stopped shrinking as the resistant
fraction became the predominant tumor fraction and tumor
quantity then began to increase. This type of tumor-quantity
kinetics can be described by a sum of two exponentials (Stein
et al., 2008, 2012). The first exponential (d, decay or regression
rate constant) describes the decrease in the quantity of the
tumor fraction susceptible or sensitive to treatment. The second
exponential (g, growth rate constant) describes the increase in
the tumor quantity derived from cells resistant or insensitive to
therapy. From the outset, both regression of sensitive tumor cells
and expansion of the resistant cells occur simultaneously. Using
this approach, one can discern a growth rate constant (g) even
while the tumor is shrinking, and this growth rate constant
explains the apparent deviation from a pure exponential decay
of the tumor kinetics.
The postprotocol survival (PPS) endpoint, defined as the
time interval from the time when protocol therapy ended to the
time of death from any cause, was evaluated for both arms of
the trial. As shown in Figure 1B, patients initially randomized to
the interferon alfa arm had a longer median PPS in comparison
to those assigned to receive sunitinib (medians: 29.1 versus
18.7 weeks, p = 0.006). While at first this might be interpreted
as evidence that sunitinib ‘‘accelerated’’ the rate of tumor growth
after its discontinuation, in fact, this most likely reflects the
‘‘postprotocol’’ treatment and management of patients (Motzer
et al., 2007, 2009). Specifically,z60% patients initially random-
ized to interferon alfa eventually received sunitinib or another
VEGFR inhibitor, agents that we now know delay progression
when administered. By comparison, only 20% of patients initially
randomized to sunitinib received a cytokine as subsequent
therapy, meaning that a lower percentage of patients initially
treated with sunitinib received as a postprotocol therapy a treat-278 Cell Reports 3, 277–281, February 21, 2013 ª2013 The Authorsment known to be effective against metastatic renal cell carci-
noma. Note here that at the time the study was conducted other
therapies now available had not yet been approved for the
treatment of metastatic renal cell carcinoma. We also cannot
exclude the possibility that interferon alfa triggered an immune
response in some patients that could have extended their lives
‘‘postprotocol.’’ The important point is that these confounding
variables and not discontinuation of sunitinib could explain the
differences in PPS. Furthermore, we would note here that
patients randomized to receive sunitinib in fact survived longer
than those assigned initially to interferon alfa, by 4.6 months
(median overall survival [OS] 26.4 months for sunitinib versus
21.8 months for interferon alfa), again making any postprotocol
acceleration highly unlikely (Motzer et al., 2009). Finally, we
would note that patients initially randomized to sunitinib received
the experimental therapy nearly 7 months longer than those
initially assigned to interferon alfa (median durations of treatment
11 months versus 4 months) (Motzer et al., 2009).
While a comparison of patients according to their randomized
treatment assignments cannot be done given the confounding
variables discussed in the preceding paragraph, ample evidence
within the sunitinib data argues strongly against the possibility
that tumors ‘‘accelerated’’ after discontinuation of sunitinib
therapy. For example, were treatment with sunitinib harmful,
one would have expected greater harm to come to those who
received sunitinib longer. However that was not the case, as
shown when one examines the dependence of PPS on the
time on treatment (TOT). TOT is the time from randomization to
the time when treatment ceased for any reason, including death,
toxicity, or an increase in tumor size by 20% in the longest diam-
eter above the minimum length observed during the study. As
shown in Figure 2, longer TOT, indicative of a patient receiving
Figure 3. Tumor Response and Treatment Outcomes
(A–D) Correlations between tumor response to sunitinib assessed as the ratio
(Minimum/Initial) of the minimal tumor quantity (Minimum) measured while
receiving therapy to the initial tumor quantity (Initial) at the start of therapy and
either TOT (A, all patients, and B, all patients with date of death as in C and D),
OS (C), or PPS (D). The data demonstrate the lack of an effect of sunitinib
efficacy assessed as the ratio Minimum/Initial on PPS (Rsq = 0.0099, p =
0.1837), but modest effects on TOT (Rsq = 0.31, p < 0.001 for both A and B) and
OS (Rsq = 0.21, p < 0.001).
Figure 4. Tumor Growth Rates and Treatment Outcomes
(A–D) Correlations between sunitinib efficacy in individual patients assessed
as the on-study growth rate constant (g) derived using tumor measurements
while receiving sunitinib therapy and either TOT (A, all patients; and B, all
patients with date of death as in C and D), OS (C), or PPS (D). The data
demonstrate the lack of an effect of sunitinib efficacy assessed as the on-study
growth rate constant on PPS (Rsq = 0.000, p = 0.9586), but modest effects on
TOT (Rsq = 0.41, p < 0.001 for A; and Rsq = 0.34, p < 0.001 for B) and OS (Rsq =
0.28, p < 0.001). Note that data similar to that depicted in (D) were previously
published (Stein et al., 2012).greater quantities of sunitinib, did not compromise a patient’s
PPS (slope of regression line = 0.054, 95% confidence interval
0.189, 0.048), indicating that greater sunitinib exposure did not
adversely impact PPS. TOT, however, did have an impact onOS,
and, as Figure 2B shows, this was favorable, with patients
receiving sunitinib for longer times also surviving longer. The
latter is not surprising, given that longer treatment would have
been administered to those benefiting from sunitinib and the
longer the benefit the better the outcome.
Furthermore, if sunitinib were harmful, one could also expect
that greater harm would come from a greater sunitinib effect
on tumors, reflecting a greater effect on the tumor vasculature
if indeed this is the drug’s target in humans. However, as shown
in Figure 3, when examining the results obtained for TOT, PPS,
and OS against the relative tumor quantity reduction, one cannot
find any evidence of a harmful sunitinib effect. In this analysis, the
sunitinib effect on the tumors of an individual patient—tumor
response—is described by the extent of tumor shrinkage,
defined as the ratio between the smallest tumor quantity ob-
served during treatment (minimum) and the tumor quantity at
the beginning of treatment (initial). Tumor response, analyzed
as a continuous variable, correlates modestly with TOT (Figures
3A and 3B) and with OS (Figure 3C) but not with PPS (Figure 3D).
Note here that these are relative values, not absolute ones; they
reflect the drug’s effect on the tumor but do not consider the
absolute quantity of tumor, so one should not expect those
with the lowest minimal to initial tumor quantity ratios to neces-
sarily survive longer, since both the quantity and the extent of
shrinkage of that quantity are important for survival.
Similarly, if instead of using theminimal to initial tumor quantity
as a measure of sunitinib effect on the tumors one uses the
growth rate constant (g) calculated with the use of data obtainedCwhile patients received on-study treatment, once again one
cannot find evidence that sunitinib was harmful. Specifically,
one observes positive (favorable) correlations of g with TOT
(Figures 4A and 4B), as well as with OS (Figure 4C), again
demonstrating that a greater sunitinib effect on tumors, as evi-
denced by a slower g, is not harmful and does not reduce OS.
Furthermore, the data show no correlation of on-study g with
PPS (Figure 4D), again demonstrating that a greater sunitinib
effect on the tumors did not compromise PPS. Thus, neither of
two measures of a drug’s effect on the tumor—the tumor’s
response, shown in Figure 3, nor the growth rate constant, de-
picted in Figure 4—support the notion that sunitinib was harmful;
instead, they clearly demonstrate that a greater sunitinib effect
was favorable.
DISCUSSION
Using data from the pivotal trial comparing sunitinib versus inter-
feron alfa in metastatic renal cell carcinoma, we asked whether
sunitinib adversely impacts a patient’s clinical course—espe-
cially after discontinuation—perhaps by ‘‘accelerating’’ metas-
tases, as has been suggested by preclinical studies (Ebos
et al., 2009; Pa`ez-Ribes et al., 2009). No support for disease
acceleration was found in patients receiving sunitinib. We
demonstrate again that sunitinib therapy is beneficial for patients
with mRCC. Specifically, we found no significant correlation
between the length of time patients received sunitinib treat-
ment and their postprotocol (postsunitinib) survival, indicat-
ing that longer exposure to sunitinib does not shorten survival
after its discontinuation. Indeed, the longer patients stayed on
treatment the longer their OS. Two other measures of sunitinibell Reports 3, 277–281, February 21, 2013 ª2013 The Authors 279
effect (the extent of tumor reduction and the tumor’s growth rate
constant while the patient received sunitinib) also did not corre-
late with postprotocol (postsunitinib) survival, indicating that
a greater sunitinib effect on the tumor does not portend a worse
outcome after treatment is discontinued. Indeed, our analysis
found no evidence to suggest that sunitinib alters tumor biology,
other than slowing tumor growth while administered.
The difference between these results in humans and aprevious
study demonstrating that sunitinib discontinuation led to an
‘‘acceleration’’ of the disease may reflect the known limitations
of otherwise valuablemurinemodels (Ebos et al., 2009). Amurine
model in which a small, relatively ‘‘new’’ tumor is being assessed
might differ from a situation in which a patient who has tumors
that are more ‘‘established’’ and several centimeters in size.
The former might be more dependent on ‘‘angiogenesis,’’ while
the latter has an established vascular supply. We would note
here that the mean and median tumor quantity ‘‘measured’’ in
these patients was 14.3 and 11.2 cm, and, since in a majority
of patients only a fraction of all tumor masses is measured, these
patients clearly had tumors that weremuch larger in size than the
tumors in the mice. Indeed, while sunitinib might have antiangio-
genic effects in the small tumors found in mice, its activity in
humans with metastatic renal cell carcinoma might primarily be
antiangiogenic but might also be more complex. Given its broad
inhibitory profile, inhibition of one or more kinases might also be
important, although this has yet to be proven. An additional point
is that mRCC presents as highly vascularized tumors, while the
mouse studies used cancers that in humans are less vascular.
In that respect, sunitinib may act differently on mRCC than on
other cancer types. These possibilities require further study in
humans.
We conclude thatthe clinical data for sunitinib do not indicate
that the drug has any detrimental effect on established meta-
static renal cell cancer. We would caution that we could not
draw the same conclusion for smaller, microscopic tumors,
such as those that might be encountered in an adjuvant setting.
In an adjuvant setting, sunitinib is administered after a ‘‘com-
plete’’ surgical resection in order to prevent or delay recurrence
of occult or microscopic disease. Although there is nothing in the
available evidence to suggest that adjuvant sunitinib will be
harmful, in due course this question will be answered if patients
enrolled in ongoing clinical trials evaluating adjuvant sunitinib
experience ‘‘acceleration’’ of recurrences. Regarding the latter,
we would note that now, more than 2 years after completing its
target enrollment of 1,923 patients in September 2010, the ran-
domized phase III ASSURE (Adjuvant Sorafenib or Sunitinib for
Unfavorable Renal Carcinoma) trial has not reported an adverse
outcome, making it less likely that an adverse acceleration will
be eventually reported (http://www.cancer.gov/clinicaltrials/
search/view?cdrid=478976&version=healthprofessional).
The available evidence unequivocally demonstrates that suni-
tinib reduces tumor growth while administered, improves OS,
and does not appear to alter tumor biology after treatment dis-
continuation. While continuing treatment longer to avoid a return
to ‘‘untreated’’ growth rates might be beneficial (Stein et al.,
2012), we would state with confidence that sunitinib, and most
likely similar drugs, can be given to patients with mRCCs without
fear of accelerating tumor growth. Concerns arising from animal280 Cell Reports 3, 277–281, February 21, 2013 ª2013 The Authorsmodels do not appear to apply to mRCC patients receiving
sunitinib.
EXPERIMENTAL PROCEDURES
Source of the Data and Definitions of Terms
Data, including tumor measurements, disease progression, and death dates,
were anonymized and provided by Pfizer in spreadsheet format. The study
was an international, multicenter phase 3 trial that enrolled 750 patients with
previously untreatedMRCC (Motzer et al., 2007, 2009). Patients were random-
ized to receive either interferon alfa at a dose of 9 million units subcutaneously
three times each week or repeated 6-week cycles of sunitinib administered
at a dose of 50 mg once daily for 4 weeks, followed by 2 weeks without treat-
ment. The primary endpoint was progression-free survival (PFS). Secondary
endpoints included the objective response rate (ORR), OS, patient-reported
outcomes, and safety. PFS is defined as the duration of time from the start
of treatment until (1) the time when the tumor quantity reaches a value 20%
above the nadir in patients whose tumors shrank or (2) the time when tumor
quantity reaches a value 20%above the initial in patientswhose tumor quantity
did not decrease, since in these patients the initial quantity is operationally their
‘‘nadir.’’ Additionally, in the rare patients who died before experiencing tumor
‘‘progression,’’ PFS was scored as the date of death. Assessments of tumor
size at each interval provided the necessary measurements for calculation of
individual tumor growth and regression rate constants. OS was defined as
the time from randomization to death from any cause.
Statistical Analysis and Estimation of the Growth Rate Constant
Linear regression via the SAS software was used to identify the presence or
absence of statistically meaningful correlations. Chi-square tests and the
p value were used as measures of statistical significance. The growth rate
was estimated with the use of a previously described kinetic model (Stein
et al., 2008, 2012).
LICENSING INFORMATION
This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution,
and reproduction in any medium, provided the original author and source
are credited.
ACKNOWLEDGMENTS
K.B.B. was supported by the National Science Foundation, while working at
the Foundation. Any opinion, finding, and conclusions or recommendations
expressed in this material are those of the authors and do not necessarily
reflect the views of the National Science Foundation.
Received: August 14, 2012
Revised: November 4, 2012
Accepted: January 15, 2013
Published: February 7, 2013
REFERENCES
Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G.,
and Kerbel, R.S. (2009). Accelerated metastasis after short-term treatment
with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239.
Ferrara, N. (2009). Vascular endothelial growth factor. Arterioscler. Thromb.
Vasc. Biol. 29, 789–791.
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J.
Med. 285, 1182–1186.
Folkman, J., Merler, E., Abernathy, C., and Williams, G. (1971). Isolation of
a tumor factor responsible for angiogenesis. J. Exp. Med. 133, 275–288.
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next gener-
ation. Cell 144, 646–674.
Heng, D.Y., and Kollmannsberger, C. (2010). Sunitinib. Recent Results Cancer
Res. 184, 71–82.
Kowanetz, M., and Ferrara, N. (2006). Vascular endothelial growth factor
signaling pathways: therapeutic perspective. Clin. Cancer Res. 12, 5018–
5022.
Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M.,
Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S.T., et al. (2007). Sunitinib
versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356,
115–124.
Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M.,
Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G.A., et al. (2009).
Overall survival and updated results for sunitinib compared with interferon
alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27,
3584–3590.
Papaetis, G.S., and Syrigos, K.N. (2009). Sunitinib: a multitargeted receptor
tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs
23, 377–389.
Pa`ez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vin˜als, F., In-
oue, M., Bergers, G., Hanahan, D., and Casanovas, O. (2009). AntiangiogenicCtherapy elicits malignant progression of tumors to increased local invasion and
distant metastasis. Cancer Cell 15, 220–231.
Potente, M., Gerhardt, H., and Carmeliet, P. (2011). Basic and therapeutic
aspects of angiogenesis. Cell 146, 873–887.
Stein, W.D., Yang, J., Bates, S.E., and Fojo, T. (2008). Bevacizumab reduces
the growth rate constants of renal carcinomas: a novel algorithm suggests
early discontinuation of bevacizumab resulted in a lack of survival advantage.
Oncologist 13, 1055–1062.
Stein, W.D., Wilkerson, J., Kim, S.T., Huang, X., Motzer, R.J., Fojo, A.T., and
Bates, S.E. (2012). Analyzing the pivotal trial that compared sunitinib and
IFN-a in renal cell carcinoma, using a method that assesses tumor regression
and growth. Clin. Cancer Res. 18, 2374–2381.
Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Ru-
binstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian,
M.C., and Gwyther, S.G. (2000). New guidelines to evaluate the response to
treatment in solid tumors. European Organization for Research and Treatment
of Cancer, National Cancer Institute of the United States, National Cancer
Institute of Canada. J. Natl. Cancer Inst. 92, 205–216.ell Reports 3, 277–281, February 21, 2013 ª2013 The Authors 281
